European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era

Maria J. Ribal; Philip Cornford; Alberto Briganti; Thomas Knoll; Stavros Gravas; Marek Babjuk; Christopher Harding; Alberto Breda; Axel Bex; Jens J. Rassweiler; Ali S. Gözen; Giovannalberto Pini; Evangelos Liatsikos; Gianluca Giannarini; Alex Mottrie; Ramnath Subramaniam; Nikolaos Sofikitis; Bernardo M.C. Rocco; Li Ping Xie; J. Alfred Witjes; Nicolas Mottet; Börje Ljungberg; Morgan Rouprêt; Maria P. Laguna; Andrea Salonia; Gernot Bonkat; Bertil F.M. Blok; Christian Türk; Christian Radmayr; Noam D. Kitrey; Daniel S. Engeler; Nicolaas Lumen; Oliver W. Hakenberg; Nick Watkin; Rizwan Hamid; Jonathon Olsburgh; Julie Darraugh; Robert Shepherd; Emma Jane Smith; Christopher R. Chapple; Arnulf Stenzl; Hendrik Van Poppel; Manfred Wirth; Jens Sønksen; James N'Dow; EAU Section Offices and the EAU Guidelines Panels

doi:10.1016/j.eururo.2020.04.056

European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era

Maria J. Ribal^* (Corresponding Author), Philip Cornford, Alberto Briganti, Thomas Knoll, Stavros Gravas, Marek Babjuk, Christopher Harding, Alberto Breda, Axel Bex, Jens J. Rassweiler, Ali S. Gözen, Giovannalberto Pini, Evangelos Liatsikos, Gianluca Giannarini, Alex Mottrie, Ramnath Subramaniam, Nikolaos Sofikitis, Bernardo M.C. Rocco, Li Ping Xie, J. Alfred WitjesNicolas Mottet, Börje Ljungberg, Morgan Rouprêt, Maria P. Laguna, Andrea Salonia, Gernot Bonkat, Bertil F.M. Blok, Christian Türk, Christian Radmayr, Noam D. Kitrey, Daniel S. Engeler, Nicolaas Lumen, Oliver W. Hakenberg, Nick Watkin, Rizwan Hamid, Jonathon Olsburgh, Julie Darraugh, Robert Shepherd, Emma Jane Smith, Christopher R. Chapple, Arnulf Stenzl, Hendrik Van Poppel, Manfred Wirth, Jens Sønksen, James N'Dow, EAU Section Offices and the EAU Guidelines Panels

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

231 Citations (Scopus)

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is unlike anything seen before by modern science-based medicine. Health systems across the world are struggling to manage it. Added to this struggle are the effects of social confinement and isolation. This brings into question whether the latest guidelines are relevant in this crisis. We aim to support urologists in this difficult situation by providing tools that can facilitate decision making, and to minimise the impact and risks for both patients and health professionals delivering urological care, whenever possible. We hope that the revised recommendations will assist urologist surgeons across the globe to guide the management of urological conditions during the current COVID-19 pandemic.

Original language	English
Pages (from-to)	21-28
Number of pages	8
Journal	European Urology
Volume	78
Issue number	1
DOIs	https://doi.org/10.1016/j.eururo.2020.04.056
Publication status	Published - Jul 2020

Bibliographical note

Funding Information:
Financial disclosures: Maria J. Ribal certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Maria J. Ribal received company speaker honorarium from Janssen Laboratories, Olympus Iberia S.A.U., Astellas Pharma S.A., and Ipsen Pharma; and holds a patent for “Method for non-invasive diagnosis of bladder cancer”, European Patent Office (grant number: 13382030.8-1403; entity holder: Fina Biotech, S.L.U. June 2007). Philip Cornford is a company consultant for Astellas, Ipsen, and Ferring; received company speaker honoraria from Astellas, Janssen, Ipsen, and Pfizer; participated in trials run by Ferring; and received fellowships and travel grants from Astellas and Janssen. Alberto Briganti is a company consultant for Astellas, Janssen, Opko Health, MDx Health, and Bayer; received company speaker honorarium from Astellas and Ferring; and received research support from Sandoz. Thomas Knoll is a company consultant for Storz Medical, Dornier, Olympus, and Boston Scientific; received company speaker honorarium from Boston scientific; received fellowship/travel grants from Cook; and received research support from Dornier. Stavros Gravas is a company consultant for Astellas and GSK; and has received speaker honorarium from Astellas, Pierre Fabre, and Ferring. Marek Babjuk is a company consultant for Astellas; received company speaker honoraria or consultancy fees from Ipsen Pharma s.r.o., Janssen, Olympus, and Astellas; holds an advisory board position for Ferring; and participates in trials run by Hamlet Pharma, Ferring, and Sotio. Christopher Harding is a company consultant for Teleflex Medical; received speaker honorarium from Astellas, Allergan, and Medtronic; received travel grants from Medtronic and research grants from NIHR and The Urology Foundation; and participated in a trial by Medtronic. Axel Bex has participated in a trial run by BMS. Evangelos Liatsikos is a company consultant for CooK Medical; received speaker honoraria from Boston Scientific and Karl Storz, and participates in clinical studies run by Cook Medical. Alex Mottrie is the CEO of ORSI Academy and holds equity interest in Intuitive. Li-Ping Xie participates in trials run by IPSEN (PRIORITI study) and Olympus (TVERP study) as the primary investigator. Alfred J. Witjes is a company consultant for Spectrum, Tocagen, BioClin, Sanofi Aventis, Biocancell Ltd., and Nucleix Ltd.; received honoraria or consultation fees from Taris Biomedical, BMS, MSD Global Medical Affairs, and Roche Nederland B.V.; and participated in trials run by Taris, Cepheid, Arquer, and MEL Amsterdam. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, Ipsen, Sanofi, Janssen, and Roche. Börje Ljungberg has received speaker honoraria from Pfizer, Ipsen, and BMS; has participated in studies run by Janssen, Astellas, and Medivation; and is a company consultant for Janssen, Novartis, and Ipsen Nordic. Morgan Rouprêt receives company speaker honorarium from Roche, Zambon, Ipsen Pharma, Janssen, and Astellas; receives research support from GSK, Pfizer, and Roche; receives consultancy fees from Lilly, GSK, Ipsen, Astellas, Takeda, Sanofi Pasteur, and Medac; receives company speaker honorarium from Roche and Zambon; and participates in studies by Pfizer and Roche. Gernot Bonkat has received speaker honoraria from Vifor Pharma, Bionorica, and IBSA; has received fellowship and travel grants from Vifor Pharma, Eli Lilly, and Astellas; and is a company consultant for Janssen-Cilag, Zambon, IBSA, and Vifor Pharma. Noam D. Kitrey has received speaker honorarium from Astellas and Pfizer; has participated in trials run by Astellas and Ipsen; and has received fellowship and travel grants from Pfizer. Nicolaas Lumen received company speaker honorarium from Bayer and Janssen; participated in trials run by Janssen, Roche, Pfizer Belgium, and AstraZeneca N.V.; and received grant/research support from Bayer and Janssen. Christopher R. Chapple is a consultant for Astellas, Bayer, Contura, Ferring, Pierre Fabre, Symimetic, and Urovant Sciences; received speaker honorarium from Astellas and Lupin; is an author for Allergan, Astellas, and Ferring; is an investigator for Astellas and Bayer; and is a co-patent holder for Symimetic. Arnulf Stenzl is a company consultant/advisor for Ipsen Pharma, Roche, Janssen, Alere, Bristol-Myers Squibb, Stebabiotech, Synergo, and Ferring; received speaker honorarium from Janssen, Ipsen Pharma, Sanofi Aventis, CureVac, Astellas, Amgen, and AstraZeneca; participates in clinical studies by Johnson & Johnson, Roche, Cepheid, Bayer AG, CureVac, Immatics Biotechnologies GmbH, and GemeDx Biosciences; and received research grants from AmgenInc, Immatics biotechnologies GmbH, Novartis AG, and Karl Storz AG. Jens Sønksen holds equity interests in Multicept A/S, Frederiksberg, Denmark. Jens J. Rassweiler, Ali S. Gözen, Giovannalberto Pini, Gianluca Giannarini, Bernardo M.C. Rocco, Ramnath Subramaniam, Nikolaos Sofikitis, Julie Darraugh, Emma Jane Smith, Robert Shepherd, Bertil F.M. Blok, Alberto Breda, Daniel S. Engeler, Oliver W. Hakenberg, Nick Watkin, Maria Pilar Laguna, Christian Radmayr, Andrea Salonia, Christian Türk, Hendrik van Poppel, Manfred Wirth, and James N’Dow have nothing to declare.

Keywords

Coronavirus disease 2019
European Association of Urology
Guidelines
Guidelines Office
Pandemic
Section Offices

Access to Document

10.1016/j.eururo.2020.04.056Licence: Unspecified

Fingerprint

Dive into the research topics of 'European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era'. Together they form a unique fingerprint.

Cite this

Ribal, M. J., Cornford, P., Briganti, A., Knoll, T., Gravas, S., Babjuk, M., Harding, C., Breda, A., Bex, A., Rassweiler, J. J., Gözen, A. S., Pini, G., Liatsikos, E., Giannarini, G., Mottrie, A., Subramaniam, R., Sofikitis, N., Rocco, B. M. C., Xie, L. P., ... EAU Section Offices and the EAU Guidelines Panels (2020). European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. European Urology, 78(1), 21-28. https://doi.org/10.1016/j.eururo.2020.04.056

European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. / Ribal, Maria J. (Corresponding Author); Cornford, Philip; Briganti, Alberto et al.
In: European Urology, Vol. 78, No. 1, 07.2020, p. 21-28.

Research output: Contribution to journal › Article › peer-review

Ribal, MJ, Cornford, P, Briganti, A, Knoll, T, Gravas, S, Babjuk, M, Harding, C, Breda, A, Bex, A, Rassweiler, JJ, Gözen, AS, Pini, G, Liatsikos, E, Giannarini, G, Mottrie, A, Subramaniam, R, Sofikitis, N, Rocco, BMC, Xie, LP, Witjes, JA, Mottet, N, Ljungberg, B, Rouprêt, M, Laguna, MP, Salonia, A, Bonkat, G, Blok, BFM, Türk, C, Radmayr, C, Kitrey, ND, Engeler, DS, Lumen, N, Hakenberg, OW, Watkin, N, Hamid, R, Olsburgh, J, Darraugh, J, Shepherd, R, Smith, EJ, Chapple, CR, Stenzl, A, Van Poppel, H, Wirth, M, Sønksen, J, N'Dow, J & EAU Section Offices and the EAU Guidelines Panels 2020, 'European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era', European Urology, vol. 78, no. 1, pp. 21-28. https://doi.org/10.1016/j.eururo.2020.04.056

@article{efaed581150f45fcbe5d2843ae79de1c,

title = "European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era",

abstract = "The coronavirus disease 2019 (COVID-19) pandemic is unlike anything seen before by modern science-based medicine. Health systems across the world are struggling to manage it. Added to this struggle are the effects of social confinement and isolation. This brings into question whether the latest guidelines are relevant in this crisis. We aim to support urologists in this difficult situation by providing tools that can facilitate decision making, and to minimise the impact and risks for both patients and health professionals delivering urological care, whenever possible. We hope that the revised recommendations will assist urologist surgeons across the globe to guide the management of urological conditions during the current COVID-19 pandemic.",

keywords = "Coronavirus disease 2019, European Association of Urology, Guidelines, Guidelines Office, Pandemic, Section Offices",

author = "Ribal, {Maria J.} and Philip Cornford and Alberto Briganti and Thomas Knoll and Stavros Gravas and Marek Babjuk and Christopher Harding and Alberto Breda and Axel Bex and Rassweiler, {Jens J.} and G{\"o}zen, {Ali S.} and Giovannalberto Pini and Evangelos Liatsikos and Gianluca Giannarini and Alex Mottrie and Ramnath Subramaniam and Nikolaos Sofikitis and Rocco, {Bernardo M.C.} and Xie, {Li Ping} and Witjes, {J. Alfred} and Nicolas Mottet and B{\"o}rje Ljungberg and Morgan Roupr{\^e}t and Laguna, {Maria P.} and Andrea Salonia and Gernot Bonkat and Blok, {Bertil F.M.} and Christian T{\"u}rk and Christian Radmayr and Kitrey, {Noam D.} and Engeler, {Daniel S.} and Nicolaas Lumen and Hakenberg, {Oliver W.} and Nick Watkin and Rizwan Hamid and Jonathon Olsburgh and Julie Darraugh and Robert Shepherd and Smith, {Emma Jane} and Chapple, {Christopher R.} and Arnulf Stenzl and {Van Poppel}, Hendrik and Manfred Wirth and Jens S{\o}nksen and James N'Dow and {EAU Section Offices and the EAU Guidelines Panels}",

note = "Funding Information: Financial disclosures: Maria J. Ribal certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Maria J. Ribal received company speaker honorarium from Janssen Laboratories, Olympus Iberia S.A.U., Astellas Pharma S.A., and Ipsen Pharma; and holds a patent for “Method for non-invasive diagnosis of bladder cancer”, European Patent Office (grant number: 13382030.8-1403; entity holder: Fina Biotech, S.L.U. June 2007). Philip Cornford is a company consultant for Astellas, Ipsen, and Ferring; received company speaker honoraria from Astellas, Janssen, Ipsen, and Pfizer; participated in trials run by Ferring; and received fellowships and travel grants from Astellas and Janssen. Alberto Briganti is a company consultant for Astellas, Janssen, Opko Health, MDx Health, and Bayer; received company speaker honorarium from Astellas and Ferring; and received research support from Sandoz. Thomas Knoll is a company consultant for Storz Medical, Dornier, Olympus, and Boston Scientific; received company speaker honorarium from Boston scientific; received fellowship/travel grants from Cook; and received research support from Dornier. Stavros Gravas is a company consultant for Astellas and GSK; and has received speaker honorarium from Astellas, Pierre Fabre, and Ferring. Marek Babjuk is a company consultant for Astellas; received company speaker honoraria or consultancy fees from Ipsen Pharma s.r.o., Janssen, Olympus, and Astellas; holds an advisory board position for Ferring; and participates in trials run by Hamlet Pharma, Ferring, and Sotio. Christopher Harding is a company consultant for Teleflex Medical; received speaker honorarium from Astellas, Allergan, and Medtronic; received travel grants from Medtronic and research grants from NIHR and The Urology Foundation; and participated in a trial by Medtronic. Axel Bex has participated in a trial run by BMS. Evangelos Liatsikos is a company consultant for CooK Medical; received speaker honoraria from Boston Scientific and Karl Storz, and participates in clinical studies run by Cook Medical. Alex Mottrie is the CEO of ORSI Academy and holds equity interest in Intuitive. Li-Ping Xie participates in trials run by IPSEN (PRIORITI study) and Olympus (TVERP study) as the primary investigator. Alfred J. Witjes is a company consultant for Spectrum, Tocagen, BioClin, Sanofi Aventis, Biocancell Ltd., and Nucleix Ltd.; received honoraria or consultation fees from Taris Biomedical, BMS, MSD Global Medical Affairs, and Roche Nederland B.V.; and participated in trials run by Taris, Cepheid, Arquer, and MEL Amsterdam. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, Ipsen, Sanofi, Janssen, and Roche. B{\"o}rje Ljungberg has received speaker honoraria from Pfizer, Ipsen, and BMS; has participated in studies run by Janssen, Astellas, and Medivation; and is a company consultant for Janssen, Novartis, and Ipsen Nordic. Morgan Roupr{\^e}t receives company speaker honorarium from Roche, Zambon, Ipsen Pharma, Janssen, and Astellas; receives research support from GSK, Pfizer, and Roche; receives consultancy fees from Lilly, GSK, Ipsen, Astellas, Takeda, Sanofi Pasteur, and Medac; receives company speaker honorarium from Roche and Zambon; and participates in studies by Pfizer and Roche. Gernot Bonkat has received speaker honoraria from Vifor Pharma, Bionorica, and IBSA; has received fellowship and travel grants from Vifor Pharma, Eli Lilly, and Astellas; and is a company consultant for Janssen-Cilag, Zambon, IBSA, and Vifor Pharma. Noam D. Kitrey has received speaker honorarium from Astellas and Pfizer; has participated in trials run by Astellas and Ipsen; and has received fellowship and travel grants from Pfizer. Nicolaas Lumen received company speaker honorarium from Bayer and Janssen; participated in trials run by Janssen, Roche, Pfizer Belgium, and AstraZeneca N.V.; and received grant/research support from Bayer and Janssen. Christopher R. Chapple is a consultant for Astellas, Bayer, Contura, Ferring, Pierre Fabre, Symimetic, and Urovant Sciences; received speaker honorarium from Astellas and Lupin; is an author for Allergan, Astellas, and Ferring; is an investigator for Astellas and Bayer; and is a co-patent holder for Symimetic. Arnulf Stenzl is a company consultant/advisor for Ipsen Pharma, Roche, Janssen, Alere, Bristol-Myers Squibb, Stebabiotech, Synergo, and Ferring; received speaker honorarium from Janssen, Ipsen Pharma, Sanofi Aventis, CureVac, Astellas, Amgen, and AstraZeneca; participates in clinical studies by Johnson & Johnson, Roche, Cepheid, Bayer AG, CureVac, Immatics Biotechnologies GmbH, and GemeDx Biosciences; and received research grants from AmgenInc, Immatics biotechnologies GmbH, Novartis AG, and Karl Storz AG. Jens S{\o}nksen holds equity interests in Multicept A/S, Frederiksberg, Denmark. Jens J. Rassweiler, Ali S. G{\"o}zen, Giovannalberto Pini, Gianluca Giannarini, Bernardo M.C. Rocco, Ramnath Subramaniam, Nikolaos Sofikitis, Julie Darraugh, Emma Jane Smith, Robert Shepherd, Bertil F.M. Blok, Alberto Breda, Daniel S. Engeler, Oliver W. Hakenberg, Nick Watkin, Maria Pilar Laguna, Christian Radmayr, Andrea Salonia, Christian T{\"u}rk, Hendrik van Poppel, Manfred Wirth, and James N{\textquoteright}Dow have nothing to declare. ",

year = "2020",

month = jul,

doi = "10.1016/j.eururo.2020.04.056",

language = "English",

volume = "78",

pages = "21--28",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - European Association of Urology Guidelines Office Rapid Reaction Group

T2 - An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era

AU - Ribal, Maria J.

AU - Cornford, Philip

AU - Briganti, Alberto

AU - Knoll, Thomas

AU - Gravas, Stavros

AU - Babjuk, Marek

AU - Harding, Christopher

AU - Breda, Alberto

AU - Bex, Axel

AU - Rassweiler, Jens J.

AU - Gözen, Ali S.

AU - Pini, Giovannalberto

AU - Liatsikos, Evangelos

AU - Giannarini, Gianluca

AU - Mottrie, Alex

AU - Subramaniam, Ramnath

AU - Sofikitis, Nikolaos

AU - Rocco, Bernardo M.C.

AU - Xie, Li Ping

AU - Witjes, J. Alfred

AU - Mottet, Nicolas

AU - Ljungberg, Börje

AU - Rouprêt, Morgan

AU - Laguna, Maria P.

AU - Salonia, Andrea

AU - Bonkat, Gernot

AU - Blok, Bertil F.M.

AU - Türk, Christian

AU - Radmayr, Christian

AU - Kitrey, Noam D.

AU - Engeler, Daniel S.

AU - Lumen, Nicolaas

AU - Hakenberg, Oliver W.

AU - Watkin, Nick

AU - Hamid, Rizwan

AU - Olsburgh, Jonathon

AU - Darraugh, Julie

AU - Shepherd, Robert

AU - Smith, Emma Jane

AU - Chapple, Christopher R.

AU - Stenzl, Arnulf

AU - Van Poppel, Hendrik

AU - Wirth, Manfred

AU - Sønksen, Jens

AU - N'Dow, James

AU - EAU Section Offices and the EAU Guidelines Panels

N1 - Funding Information: Financial disclosures: Maria J. Ribal certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Maria J. Ribal received company speaker honorarium from Janssen Laboratories, Olympus Iberia S.A.U., Astellas Pharma S.A., and Ipsen Pharma; and holds a patent for “Method for non-invasive diagnosis of bladder cancer”, European Patent Office (grant number: 13382030.8-1403; entity holder: Fina Biotech, S.L.U. June 2007). Philip Cornford is a company consultant for Astellas, Ipsen, and Ferring; received company speaker honoraria from Astellas, Janssen, Ipsen, and Pfizer; participated in trials run by Ferring; and received fellowships and travel grants from Astellas and Janssen. Alberto Briganti is a company consultant for Astellas, Janssen, Opko Health, MDx Health, and Bayer; received company speaker honorarium from Astellas and Ferring; and received research support from Sandoz. Thomas Knoll is a company consultant for Storz Medical, Dornier, Olympus, and Boston Scientific; received company speaker honorarium from Boston scientific; received fellowship/travel grants from Cook; and received research support from Dornier. Stavros Gravas is a company consultant for Astellas and GSK; and has received speaker honorarium from Astellas, Pierre Fabre, and Ferring. Marek Babjuk is a company consultant for Astellas; received company speaker honoraria or consultancy fees from Ipsen Pharma s.r.o., Janssen, Olympus, and Astellas; holds an advisory board position for Ferring; and participates in trials run by Hamlet Pharma, Ferring, and Sotio. Christopher Harding is a company consultant for Teleflex Medical; received speaker honorarium from Astellas, Allergan, and Medtronic; received travel grants from Medtronic and research grants from NIHR and The Urology Foundation; and participated in a trial by Medtronic. Axel Bex has participated in a trial run by BMS. Evangelos Liatsikos is a company consultant for CooK Medical; received speaker honoraria from Boston Scientific and Karl Storz, and participates in clinical studies run by Cook Medical. Alex Mottrie is the CEO of ORSI Academy and holds equity interest in Intuitive. Li-Ping Xie participates in trials run by IPSEN (PRIORITI study) and Olympus (TVERP study) as the primary investigator. Alfred J. Witjes is a company consultant for Spectrum, Tocagen, BioClin, Sanofi Aventis, Biocancell Ltd., and Nucleix Ltd.; received honoraria or consultation fees from Taris Biomedical, BMS, MSD Global Medical Affairs, and Roche Nederland B.V.; and participated in trials run by Taris, Cepheid, Arquer, and MEL Amsterdam. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, Ipsen, Sanofi, Janssen, and Roche. Börje Ljungberg has received speaker honoraria from Pfizer, Ipsen, and BMS; has participated in studies run by Janssen, Astellas, and Medivation; and is a company consultant for Janssen, Novartis, and Ipsen Nordic. Morgan Rouprêt receives company speaker honorarium from Roche, Zambon, Ipsen Pharma, Janssen, and Astellas; receives research support from GSK, Pfizer, and Roche; receives consultancy fees from Lilly, GSK, Ipsen, Astellas, Takeda, Sanofi Pasteur, and Medac; receives company speaker honorarium from Roche and Zambon; and participates in studies by Pfizer and Roche. Gernot Bonkat has received speaker honoraria from Vifor Pharma, Bionorica, and IBSA; has received fellowship and travel grants from Vifor Pharma, Eli Lilly, and Astellas; and is a company consultant for Janssen-Cilag, Zambon, IBSA, and Vifor Pharma. Noam D. Kitrey has received speaker honorarium from Astellas and Pfizer; has participated in trials run by Astellas and Ipsen; and has received fellowship and travel grants from Pfizer. Nicolaas Lumen received company speaker honorarium from Bayer and Janssen; participated in trials run by Janssen, Roche, Pfizer Belgium, and AstraZeneca N.V.; and received grant/research support from Bayer and Janssen. Christopher R. Chapple is a consultant for Astellas, Bayer, Contura, Ferring, Pierre Fabre, Symimetic, and Urovant Sciences; received speaker honorarium from Astellas and Lupin; is an author for Allergan, Astellas, and Ferring; is an investigator for Astellas and Bayer; and is a co-patent holder for Symimetic. Arnulf Stenzl is a company consultant/advisor for Ipsen Pharma, Roche, Janssen, Alere, Bristol-Myers Squibb, Stebabiotech, Synergo, and Ferring; received speaker honorarium from Janssen, Ipsen Pharma, Sanofi Aventis, CureVac, Astellas, Amgen, and AstraZeneca; participates in clinical studies by Johnson & Johnson, Roche, Cepheid, Bayer AG, CureVac, Immatics Biotechnologies GmbH, and GemeDx Biosciences; and received research grants from AmgenInc, Immatics biotechnologies GmbH, Novartis AG, and Karl Storz AG. Jens Sønksen holds equity interests in Multicept A/S, Frederiksberg, Denmark. Jens J. Rassweiler, Ali S. Gözen, Giovannalberto Pini, Gianluca Giannarini, Bernardo M.C. Rocco, Ramnath Subramaniam, Nikolaos Sofikitis, Julie Darraugh, Emma Jane Smith, Robert Shepherd, Bertil F.M. Blok, Alberto Breda, Daniel S. Engeler, Oliver W. Hakenberg, Nick Watkin, Maria Pilar Laguna, Christian Radmayr, Andrea Salonia, Christian Türk, Hendrik van Poppel, Manfred Wirth, and James N’Dow have nothing to declare.

PY - 2020/7

Y1 - 2020/7

N2 - The coronavirus disease 2019 (COVID-19) pandemic is unlike anything seen before by modern science-based medicine. Health systems across the world are struggling to manage it. Added to this struggle are the effects of social confinement and isolation. This brings into question whether the latest guidelines are relevant in this crisis. We aim to support urologists in this difficult situation by providing tools that can facilitate decision making, and to minimise the impact and risks for both patients and health professionals delivering urological care, whenever possible. We hope that the revised recommendations will assist urologist surgeons across the globe to guide the management of urological conditions during the current COVID-19 pandemic.

AB - The coronavirus disease 2019 (COVID-19) pandemic is unlike anything seen before by modern science-based medicine. Health systems across the world are struggling to manage it. Added to this struggle are the effects of social confinement and isolation. This brings into question whether the latest guidelines are relevant in this crisis. We aim to support urologists in this difficult situation by providing tools that can facilitate decision making, and to minimise the impact and risks for both patients and health professionals delivering urological care, whenever possible. We hope that the revised recommendations will assist urologist surgeons across the globe to guide the management of urological conditions during the current COVID-19 pandemic.

KW - Coronavirus disease 2019

KW - European Association of Urology

KW - Guidelines

KW - Guidelines Office

KW - Pandemic

KW - Section Offices

UR - http://www.scopus.com/inward/record.url?scp=85084140244&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.04.056

DO - 10.1016/j.eururo.2020.04.056

M3 - Article

C2 - 32376137

AN - SCOPUS:85084140244

SN - 0302-2838

VL - 78

SP - 21

EP - 28

JO - European Urology

JF - European Urology

IS - 1

ER -

European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this